The panelist summarizes the major findings from MARIPOSA-2 and their conclusions about amivantamab regimens improving outcomes in osimertinib-resistant NSCLC.
Taletrectinib Increases Already Broad Selection of ROS1+ NSCLC Therapies
Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.
Practice-Changing Lung Cancer Data From The 2025 ASCO Annual Meeting
Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.
Zidesamtinib May Yield Meaningful Outcomes in Advanced ROS1+ NSCLC
Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.
Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC
Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.
Sugemalimab/Chemotherapy Improves Long-Term Survival in Metastatic NSCLC
Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.
FDA Approves Taletrectinib in ROS1+ NSCLC
Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.